Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo targets deadly brain tumors in groundbreaking trial

NCT ID NCT07391215

Summary

This trial is testing whether adding a new drug called paxalisib to standard chemotherapy (temozolomide) is safe and can better control aggressive brain tumors like glioblastoma. It will enroll about 64 adults with specific genetic features in their tumors. The study aims to see if this combination can slow tumor growth and extend survival for patients who have few other options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME (GBM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Royal Marden NHS Foundation Trust

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.